RUTHERFORD, N.J., Feb. 08, 2016 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI” or “The Company”), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, announces that President and CEO Panna Sharma is scheduled to present a corporate overview and participate in an industry roundtable conference at Source Capital Group’s 2016 Disruptive Growth & Healthcare Conference.
The Company is scheduled to present its corporate overview on Wednesday, February 10th at 10:15 a.m. Eastern time. Additionally, Mr. Sharma will participate in the Diagnostics Panel industry discussion on Wednesday, February 10th at 9:00 a.m. Eastern time. The panel will cover disruptive innovations and business models, molecular diagnostics and reimbursement as well as emerging technologies such as next generation sequencing and immunotherapy.
Source Capital Group's 2016 Disruptive Growth & Healthcare Conference will feature presentations by C-suite executives from life science companies focusing on solutions to unmet medical needs and growth companies using disruptive technologies and business models. Attendees will include over 400 institutional investors, family offices, analysts, registered investment advisors, wealth managers, and their clients.
For additional information on the conference, including registration and company participation, please click here for additional information.
Conference Location: CONVENE, 730 Third Avenue, New York, New York
About Cancer Genetics
Cancer Genetics Inc. is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, India and China. We have established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.
The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State.
For more information, please visit or follow CGI at:
Forward Looking Statements
This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements.
Any statements that are not historical fact (including, but not limited to, statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, risks of cancellation of customer contracts or discontinuance of trials, risks that anticipated benefits from acquisitions will not be realized, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Cancer Genetics, Inc. Forms 10-K for the year ended December 31, 2014 and 10-Q for the quarter ended September 30, 2015 along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics, Inc. disclaims any obligation to update these forward-looking statements.
Contact: Media Contact: Cancer Genetics, Inc. Marie-Agnes Patrone-Michellod, PhD. Tel: 201.528.9200 Email: email@example.com
Source:Cancer Genetics, Inc.